Homologous Recombination Related Signatures Predict Prognosis and Immunotherapy Response in Metastatic Urothelial Carcinoma

Pan Li¹, Chaohu Chen¹, Jianpeng Li¹, Li Yang¹,²,³, Yuhan Wang¹, Zhilong Dong¹,²,³, Jun Mi¹,²,³, Yunxin Zhang¹,²,³, Juan Wang¹, Hanzhang Wang⁴, Ronald Rodriguez⁴, Junqiang Tian¹,²,³*, and Zhiping Wang¹,²,³*

¹Department of Urology, Lanzhou University Second Hospital, Lanzhou, China, ²Key Laboratory of Gansu Province for Urological Diseases, Lanzhou, China, ³Clinical Center of Gansu Province for Nephron-Urology, Lanzhou, China, ⁴Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States

Objective: This study used homologous recombination (HR) related signatures to develop a clinical prediction model for screening immune checkpoint inhibitors (ICIs) advantaged populations and identify hub genes in advanced metastatic urothelial carcinoma.

Methods: The single-sample gene enrichment analysis and weighted gene co-expression network analysis were applied to identify modules associated with immune response and HR in IMvigor210 cohort samples. The principal component analysis was utilized to determine the differences in HR-related module gene signature scores across different tissue subtypes and clinical variables. Risk prediction models and nomograms were developed using differential gene expression analysis associated with HR scores, least absolute shrinkage and selection operator, and multivariate proportional hazards model regression. Additionally, hub genes were identified by analyzing the contribution of HR-related genes to principal components and overall survival analysis. Finally, clinical features from GSE133624, GSE13507, the TCGA, and other data sets were analyzed to validate the relationship between hub genes and tumor growth and mutation.

Results: The HR score was significantly higher in the complete/partial response group than in the stable/progressive disease group. The majority of genes associated with HR were discovered to be involved in the cell cycle and others. Genomically unstable, high tumor level, and high immune level samples all exhibited significantly higher HR score than other sample categories, and higher HR scores were related to improved survival following ICIs treatment. The risk scores for AUNIP, SEPT, FAM72D, CAMKV, CXCL9, and FOXN4 were identified, and the training and verification groups had markedly different survival times. The risk score, tumor neoantigen burden, mismatch repair, and cell cycle regulation were discovered to be independent predictors of survival time following immunotherapy. Patients with a high level of expression of hub genes such as EME1, RAD51AP1, and RAD54L had a greater chance of surviving following immunotherapy. These genes are expressed at significantly higher levels in tumors, high-grade cancer, and invasive cancer than other categories, and are associated with TP53 and RB1 mutations.
**INTRODUCTION**

Urothelial carcinoma (UC) is the 10th most common type of cancer worldwide, predicted to cause 573,000 new cases and 213,000 deaths in 2020 alone (Sung et al., 2021). In industrialized countries, UC fatality rates have declined dramatically in recent years as a result of breakthroughs in prevention, early detection, and improved treatment (Babjuk et al., 2013). In the United States, the 5 years survival rate of patients with the early diagnosis is 95.8% because of multiple treatments such as surgery and bladder perfusion, while patients with metastatic urothelial carcinoma (mUC) is only 4.6% due to treatment limitations (Saginala et al., 2020). As a result, experts worldwide have been working nonstop to increase the survival rate of individuals with mUC.

Although platinum-based chemotherapy is the first-line treatment option for patients with mUC, cytotoxic drugs can cause clinical internal resistance, systemic toxicity, and other serious side effects, and approximately half of the patients should not be treated with platinum-based chemotherapy due to their age and pre-existing diseases (Klein and Hambley, 2009; Patel et al., 2020). Bacillus calmette guerin infusion, immune checkpoint inhibitors (ICIs), and other immunomodulatory therapy have all emerged as effective innovative therapeutics for mUC patients in recent years (Song et al., 2019). The United States Food and Drug Administration (FDA) has licensed several immunotherapy medicines (e.g., pembrolizumab, atezolizumab) for the first- or second-line treatment of individuals with mUC. While some individuals benefit from these treatments, between 70% and 80% of patients do not (Massard et al., 2016). In 2018, the FDA revised its license to require that ICIs be used exclusively in patients with mUC who do not respond to platinum-based chemotherapy but are positive for PD-L1 (Parikh et al., 2019). However, recent research indicates that the therapeutic benefit of PD-L1 is dependent on its expression on tumor-infiltrating immune cells, rather than on tumor cells (Mariathasan et al., 2018). At the same time, numerous technical issues limit the detection of PD-L1 expression, including the fact that it is easily missed in small biopsy samples, and the detection antibody’s PD-L1 binding is unstable (Topalian et al., 2016). As a result, the development of novel molecular markers capable of identifying prospective dominant populations is critical.

Tumor immunotherapy’s goal is to prevent tumor immune escape by inhibiting immunological checkpoints and to stimulate the immune system with neoantigens created by tumor-specific mutations (Hu et al., 2018). As a result, tumor mutation burden (TMB) and tumor neoantigen burden (TNB) can be utilized to predict the efficacy of ICIs (Chan et al., 2019; Wang et al., 2021).

A recent study has revealed that the DNA damage repair (DDR) pathway is not only connected with platinum chemotherapeutic drug susceptibility, but also with tumor mutation. As a result of these alterations, genomically instability, neoantigen generation, and upregulation of PD-L1 expression occur (Jiang et al., 2021). Additionally, Park et al. (2019) found that abnormal mutations in both the double-stranded and single-stranded DNA damage repair pathways are related to TMB in patients with small-cell lung cancer. Homologous recombination (HR) contributes to gene stability in two ways, it is a highly accurate repair process that maintains genomic stability when double-stranded DNA is damaged in normal cells, but it can result in genomic instability when hyperactive. For example, Shammas et al. (2009) discovered that HR is particularly active in myeloma and that inhibiting them considerably reduces genomically instability. As a consequence, studying HR-mediated immune responses and tumor alterations are essential.

In this study, the relationship between different DDR pathways and immunotherapy response was deeply analyzed, and a clinical prognosis model based on the HR signature was constructed. This model can be used to predict the prognosis of mUC patients following immunotherapy and to identify potential hub genes, paving the path for more basic experimental studies.

**DATA AND METHODS**

**Data Sources**

Clinical characteristics and tumor tissue transcriptome counts for mUC patients were collected from the IMvigor210 cohort (http://research-pub.gene.com/IMvigor210CoreBiologie_s/packageVersions/) (Mariathasan et al., 2018), a phase 2 clinical investigation of atezolizumab in advanced mUC. The study removed samples from patients whose treatment outcomes were unknown. 298 samples were ultimately obtained. Additionally, the study obtained the expression profiles of 165 primary bladder cancer samples and 21 paired tissue samples from the GSE13507 and GSE133624 in GEO database (https://www.ncbi.nlm.nih.gov/geo/), and the TCGA BLCA transcriptome counts sequencing data and sample characteristic data from UCSC Xena (http://xena.ucsc.edu/) and Thorsson et al. (2018). The study obtained 397 tumor transcriptome data, removing samples with no discernible immunological subtype and several samples from the same patient. For future analysis, RNAseq transcriptome data were transformed to transcripts per million the data for the chip expression profile data were normalized using the “limma” package’s functions. The workflow was displayed in Figure 1.
Single Sample Gene Set Enrichment Analysis

ssGSEA is a nonparametric method for normalizing the gene expression values in a given sample and generating enrichment scores based on the empirical cumulative distribution functions of the signature genes and the remaining genes (Barbie et al., 2009). Ten gene sets representing distinct DDR pathways were retrieved from the literature (Kang et al., 2012) and ssGSEA analysis was conducted using the “GSVA” package in R4.1.1 (R Foundation for Statistical Computing, Vienna, Austria) (Hänzelmann et al., 2013). Then, the study examined the association between the DDR pathway enrichment score and immunological response.

Weighted Gene Co-Expression Network Analysis

The purpose of WGCNA is to identify co-expressed gene modules and to investigate the relationship between gene networks and the targeted phenotypes, as well as the network’s hub genes (Zhang and Horvath, 2005). According to the WGCNA official guidance document (https://horvath.genetics.ucla.edu/html/CoexpressionNetwork/Rpackages/WGCNA/), the study evaluated the top 5000 genes according to the median absolute deviation for WGCNA and associated immunotherapy response, enrichment score of DDR-related pathways, and other features using the “WGCNA” package. Modules with a cluster height less than 0.25 are merged to eliminate duplicates (Langfelder and Horvath, 2008).
Function Analysis
Gene ontology (GO) analysis calculates p values for provided gene sets in biological processes, molecular functions, cellular components, and major pathways using the hypergeometric distribution approach. Determine whether the number of genes in a particular gene set surpasses the number of genes that would be expected randomly in terms of function or route. Enrichment of gene ontology analysis of genes inside each module using the anRichment program (https://horvath.genomics.ucla.edu/html/CoexpressionNetwork/GeneAnnotation/). The three most significant components were eliminated based on the p-value.

Principal Component Analysis
Principal component analysis (PCA) is a technique for reducing high-dimensional data sets to low-dimensional data sets. Its scores are weighted according to the importance of each gene in the first principal component, resulting in a weighted average that can be used to assess the biological functions of signature genes (Berglund et al., 2017). The “IOBR” package’s PCA method was utilized to perform feature scoring on samples based on HR-related modules (Zeng et al., 2021). The tissue subtypes of the samples in the research cohort were determined using the “BLCAsubtyping” package (Kamoun et al., 2020). The study investigated the distribution of HR scores among subtypes, tumor level, immune level, and overall survival.

Difference Analysis
The “Maxstat” package was used to determine the optimal survival threshold for HR scores from IMvigor210 cohort samples divided into high and low expression groups (Lausen and Schumacher, 1992). The differentially expressed gene (DEGs) screening standard used to develop the clinical prognosis model of tumor immunotherapy was the use of the “Desq2” package (Love et al., 2014), filter genes count expresses overall less than 10, log2[Fold Change] >1 and p.adj<0.05 were used to identify DEGs.

Construction of Risk Prediction Model
In a 7:3 ratio, the IMvigor210 cohort was divided into training and validation groups. In the training group, the least absolute shrinkage and selection operator (LASSO) COX regression model was generated using pairs of differential genes from the “glmnet” package, and the lambda value with the lowest value was chosen as the optimal lambda value (Simon et al., 2011). The selected variables were included in the multivariate COX regression model, and variables that did not support the proportional hazards hypothesis were eliminated from the second regression. The “rms” package was used to calculate the variance inflation factor of each variable and assess whether the model’s variables’ expressions were multicollinear, and ultimately, derive the risk variables and risk coefficients.

\[
\text{Risk score} = \sum_{i=1}^{n} (\text{Expression mRNA}_i \times \text{Coefficient mRNA}_i)
\]

The samples were separated into high and low risk groups based on their median risk score, and KM survival analysis was performed on the training and verification groups.

Construction and Validation of a Prognostic Nomogram
On the risk score and sample feature score, a univariate COX regression analysis was conducted. The standard screening variable was \( p < 0.05 \). Following the exclusion of samples with missing variables. The stepwise regression method (https://cran.r-project.org/web/packages/My.stepwise/index.html) was utilized to filter covariates, and a multivariate COX regression prognostic model was created. The variance inflation factor threshold was adjusted at 4 to avoid multicollinearity between variables. Nomogram was developed to investigate the association between total score and one- and two-year prognoses. Finally, the calibration curve and decision curve are used to assess the model’s predictive ability.

Screening of Important Homologous Recombination Genes
The first principal component was discovered, and the primary HR related genes contributing to it were identified using the expected average contribution value \((1/\text{length (variables)} \times 100\%)\) as a criterion. Using the median gene expression value as the crucial value, samples from the IMvigor210 cohort were separated into high and low expression groups, and the log-rank test was performed to examine the difference between the expression level and the immunotherapy prognosis level. To ensure that \( p < 0.05 \) was utilized as the screening threshold for module hub genes.

Verify the Relationship Between Hub Genes and Clinical Features
Transcriptome sequencing data of bladder cancer and paired paracancer samples from GSE133624 were used to analyze the expression of hub genes in tumor samples and paired normal samples. GSE13507 array expression profile data were used to analyze the differences of hub genes in different pathological grades and aggressiveness, as well as their relationship with specific survival of patients.

Analysis of Hub Genes and Tumor Progression Mechanism
Thorsson et al. (2018) scored the number of tumors in the TCGA database according to the characteristics of different biofunctional molecules. Pearson correlation analysis was conducted on hub gene expression levels and characteristic scores using the “Psych” package, and correlation heat maps were drawn. In order to \( \text{cor} > 0.7 \) and \( p < 0.001 \) as a strong correlation screening criterion. Based on the mutation data in the immunotherapy cohort, the differences of hub genes in different mutated and non-mutated samples were analyzed, and their relationships with TMB and TNB were analyzed.

Statistical Analysis
The statistics in this study were based on the software package in R4.1.1. The difference analysis of two samples for quantitative
data conforming to normal distribution adopts independent sample t-test, the non-parametric test was adopted for non-normal distribution quantitative data, the non-parametric test was adopted for various quantitative data, Chi-square test was adopted for counting data, and the log-rank test was adopted for Kaplan-Meier analysis. Correlation analysis was conducted by Pearson analysis. Take \( p < 0.05 \) was the standard of statistical significance.

RESULTS

The Homologous Recombination Enrichment Score was Considerably Greater in the Complete/Partial Response Group Than in the Stable/Progressive Disease Group

The enrichment analysis of ten different DNA damage repair pathways revealed that the HR pathway had a considerably higher enrichment score in the CR/PR group than in the SD/PD group \( (p = 0.00086) \). Base excision repair (BER), non-homologous end joining (NHEJ), translesion synthesis (TLS), and other scores were considerably lower in the CR/PR group than in the SD/PD group \( (p < 0.05) \), demonstrating that the genes involved to HR were associated with immunotherapy result (Figure 2).

Recognize Modules Involved in Immunotherapy Response and DNA Damage Repair

Immunotherapy response data, as well as HR, BER, NHEJ, OTHER, and TLS signature enrichment scores, were used to construct gene co-expression networks containing the top 5000 MDA-valued genes. The study removed samples having a cluster height of more than 130, as they were considered outliers. When the network’s soft threshold is set to 6, it is possible to design a co-expression network. These genes can be classified into eight modules according to their expression (Figures 3A–C). These modules include magenta, purple, green, tan, greenyellow, black, blue, and grey. Correlations between the green module gene co-expression network and treatment response \( (\text{cor} = 0.22, p = 1E-4) \) and HR \( (\text{cor} = 0.71, p = 5E-46) \) were significantly positive. Correlations with BER \( (\text{cor} = -0.53, p = 3E-22) \), NHEJ \( (\text{cor} = -0.73, p = 3E-49) \), OTHER \( (\text{cor} = -0.55, p = 7E-24) \), and TLS \( (\text{cor} = -0.66, p = 3E-37) \) were negative (Figure 3D). The module membership (MM) and treatment response \( (\text{cor} = 0.74, p = 5.5E-83) \), HR \( (\text{cor} = 0.94, p = 1E-200) \), BER \( (\text{cor} = 0.74, p = 5.5E-83) \), NHEJ \( (\text{cor} = 0.9, p = 1.3E-171) \), OTHER \( (\text{cor} = 0.82, p = 5.7E-116) \), TLS \( (\text{cor} = 0.92, p = 2.5E-193) \), and OTHER gene signatures were significantly correlated (Figures 3E–J). Finally, the green module’s 472 genes were used to generate the HR-related gene signature of uUC patients.

Module-Level Study of Gene Ontology Functions

The WGCNA modules were analyzed using the GO function analysis, and the results indicated that green modules with a significant positive correlation with immunotherapy response and a high HR enrichment score were primarily enriched in the cell cycle (GO:BP: 0007049), cell cycle process (GO:BP: 0022402), and mitotic cell cycle (GO:BP: 0000278). Negatively correlated black modules included exterior encapsulating structure (GO:CC: 0030312), extracellular matrix (GO:CC: 0031012), collagen-containing extracellular matrix (GO:CC: 0062023), and others. Immunological response (GO:BP:
FIGURE 3 | Construction of gene weighted co-expression network. (A) Sample cluster diagram. (B) Analysis of the scale-free topology model fit index for soft threshold powers (β). (C) A cluster dendrogram was built based on the dissimilarity of the topological overlap, which presents different gene co-expression modules in IMvigor210, modules with a clustering degree less than 0.25 were merged. (D) Heatmap analysis of the correlation between module eigengenes of IMvigor210 and enrichment score of DNA damage repair pathway. (E–J), The scatterplot of GS for the response, different enrichment score of DNA damage repair pathway vs. MM in the green module. FA/HR, Fanconi Anemia/homologous recombination; BER, base excision repair; NHEJ, non-homologous end joining; OTHER, other; TLS, translesion synthesis; GS, gene significance; MM, module membership.
006955), immune system process (GO:BP: 0002376), leukocyte activation (GO:BP: 0045321), and other immune reaction-related GO items were primarily enriched in the blue module (Table 1).

### The Homologous Recombination Scores of Several Feature Samples Varied Significantly

The signatures of HR-related modules were scored using PCA. The results indicated that the HR scores of the Lund2, TCGA, MDA, and Baylor subtypes were substantially different ($p < 0.05$) (Figures 4A–D). The Lund2 subtype had a considerably higher score of genomically instability than the other subtypes, and the sample composition score of genomically instability in the CR/PR group (36.76%) was significantly greater than that in the SD/PD group (12.17%). Neuronal (TCGA), luminal (MDA), and Baylor subtypes were substantially different ($p < 0.05$) (Figures 4F,G). The overall survival rate for patients with a high score was substantially greater than that of patients with a low score ($p < 0.05$) (Figures 4H,I).

### Clinical Features and Functional Gene Expression Were Different Across Groups With High and Low Homologous Recombination Score

The study divided the samples into groups according to the ideal survival threshold for HR score and discovered that when the critical HR score was 2.34, the overall survival Kaplan-Meier analysis of the high and low score groups was the most significant ($p < 0.001$) (Figures 4–I). There were significant differences in treatment response, tumor level, immune level, TCGA subtype, and immunophenotype between the two groups ($p < 0.05$), but not in gender, intravesical BCG infusion, smoking history, metastatic site, or other features ($p > 0.05$) (Table 2). The comparison of high and low HR score samples revealed that TMB and the number of mutations in TP53, RB1, FBXW7, LRP1B, CCND3, FGFR3, TSC1, and HRAS were considerably higher in the high score group than in the low score group. Additionally, genes are involved in biological processes such as the cell cycle, DNA replication, histones, HR, DDR, mismatch repair, nucleotide excision repair, immune checkpoint, and CD8+ T-effector had significant differences between the high and low groups (Figure 5).

### Identifying Prognostic Genes and Developing and Validating Risk Prognostic Models

The differential analysis of high and low group samples yielded a total of 1512 DEGs, including 797 upregulated and 715 downregulated genes. In the training group, LASSO regression was done with a lambda of 0.1422 (Figures 6A,B). Six HR-related immunotherapy prognostic genes were examined, and the risk scoring formula was derived using multivariate COX regression: Risk score = AUNIP* ($–0.09913798$) + SEPT3* ($–0.11228204$) + FAM72D* ($–1.03789188$) + CAMKV* ($–1.05763747$) + CXCL9* ($–0.15162375$) + FOXP4* ($–0.32029758$). Kaplan-Meier survival analysis using the training group’s median risk score as the threshold revealed that high-risk patients’ overall survival time was considerably shorter than that of low-risk patients in the training and validation groups ($p < 0.01$) (Figures 6C,D,F,G). Overall survival was likewise significantly worse in high-risk
patients than in low-risk patients in the TCGA BLCA cohort (without immunotherapy) at the optimum threshold (p < 0.01) (Figures 6E,H). To assess the model’s diagnostic value, a time-dependent ROC analysis was performed; the findings indicated that the AUC Max value was 0.75, indicating that the model had a high predictive value for the prognosis of patients undergoing immunotherapy (Figure 6I).

Develop a Nomogram for Survival Prediction

COX analysis was done univariately on the risk score and feature scores of the samples’ various functions, and 19 factors associated with overall survival were screened, as shown in Table 3. Variables were screened using stepwise regression, and multivariate COX regression analysis was used to generate a column chart for five variables: risk score, TNB, mismatch repair, CC Reg, and immunological checkpoint (Figure 7A). Among them, risk score and mismatch repair were independent risk factors for overall patient survival, whereas TNB and CC Reg were independent protective factors, as shown in Table 4. The calibration curve and decision curve were used to assess the total score model’s predictive value for patient survival time 1 and 2 years after immunotherapy, and the results indicated that the predicted total survival time was highly consistent with patient survival time in practice (Figures 7B,E). Patients benefited from the use of both models, and the benefit degree of model 2 (total score) was greater than that of model 1 (risk score) (Figures 7C,D,F,G).
Identify Critical Homologous Recombination-Related Genes Inside the Module

PCA was used to find the hub genes affecting HR scores. The proportion of explanatory variables in the first principal component (38.1%) was significantly greater than that in the other (Figure 8A). The intersection of the genes in the first component and the HR signature (GO: 0035825) genes in the GO database revealed that nine genes provided more than the average contribution to the ten genes obviously implicated in HR (Figures 8B,C). Additionally, survival analysis revealed that patients in the high expression group of BRIP1, EME1, FANCD2, RAD51, RAD51AP1, RAD54L, and RMI1 genes had a significantly longer overall survival time than those in the low expression group prior to immunotherapy ($p < 0.05$), and patients had a better prognosis following immunotherapy ($p < 0.05$) (Figures 8D–J).

Signature Gene Expression Was Found to be Associated With Carcinogenesis and Progression

Further examination of the relationship between signature genes and tumor occurrence and progression revealed that in patients without immunotherapy, the expression levels of seven signature genes were significantly higher in tumor tissues than in para-cancer tissues ($p < 0.05$) (Figures 9A–G). The expression levels of EME1, RAD51, RAD51AP1, and RAD54L genes were significantly

### TABLE 2 | Patient characteristics.

| Characteristic | Overall, N = 298$^1$ | HR score group | $p$ Value$^2$ |
|----------------|----------------------|----------------|--------------|
|                |                      | High, n = 129$^1$ | Low, n = 169$^1$ |               |
|                |                      | 33 (26%) | 32 (19%) |                      | 0.2           |
| Sex            |                      | 233 (78%) | 137 (81%) |                      |               |
| Female         | 65 (22%)             | 33 (26%) | 32 (19%) |                      |               |
| Male           | 233 (78%)            | 96 (74%) | 137 (81%) |                      |               |
| Response       |                      | 25 (19%) | 18 (11%) |                      | $<0.001$      |
| PR             | 43 (14%)             | 25 (19%) | 18 (11%) |                      |               |
| CR             | 25 (8.4%)            | 20 (16%) | 5 (3.0%) |                      |               |
| PD             | 167 (56%)            | 64 (50%) | 103 (61%) |                      |               |
| SD             | 63 (21%)             | 20 (16%) | 43 (25%) |                      |               |
| IC Level       |                      | 26 (20%) | 57 (34%) |                      | $<0.001$      |
| ICO            | 83 (28%)             | 26 (20%) | 57 (34%) |                      |               |
| IC1            | 112 (38%)            | 35 (27%) | 77 (46%) |                      |               |
| IC2+           | 102 (34%)            | 68 (53%) | 34 (20%) |                      |               |
| Unknown        | 1                    | 0        | 1         |                      |               |
| TC Level       |                      | 89 (69%) | 149 (89%) |                      | $<0.001$      |
| TO0            | 238 (80%)            | 89 (69%) | 149 (89%) |                      |               |
| TO1            | 17 (5.7%)            | 9 (7.0%) | 8 (4.8%) |                      |               |
| TO2+           | 42 (14%)             | 31 (24%) | 11 (6.5%) |                      |               |
| Unknown        | 1                    | 0        | 1         |                      |               |
| TCGA subtype   |                      | 27 (21%) | 80 (47%) |                      | $<0.001$      |
| I              | 107 (36%)            | 27 (21%) | 80 (47%) |                      |               |
| II             | 75 (25%)             | 46 (36%) | 29 (17%) |                      |               |
| III            | 60 (20%)             | 27 (21%) | 33 (20%) |                      |               |
| IV             | 56 (19%)             | 29 (22%) | 27 (16%) |                      |               |
| Immune phenotype |                   | 25 (23%) | 44 (33%) |                      | $0.002$       |
| Desert         | 69 (28%)             | 25 (23%) | 44 (33%) |                      |               |
| Excluded       | 113 (46%)            | 45 (41%) | 68 (51%) |                      |               |
| Inflamed       | 62 (23%)             | 40 (36%) | 22 (16%) |                      |               |
| Unknown        | 54                   | 19       | 35        |                      |               |
| Intravesical BCG |               | 103 (80%) | 128 (76%) |                      | $0.4$         |
| No             | 231 (78%)            | 103 (80%) | 128 (76%) |                      |               |
| Yes            | 67 (22%)             | 26 (20%) | 41 (24%) |                      |               |
| Tobacco History |                    | 15 (12%) | 17 (10%) |                      | $0.8$         |
| Current        | 32 (11%)             | 15 (12%) | 17 (10%) |                      |               |
| Never          | 98 (33%)             | 40 (31%) | 58 (34%) |                      |               |
| Previous       | 168 (56%)            | 74 (57%) | 94 (56%) |                      |               |
| Met Disease Status |            | 33 (29%) | 48 (30%) |                      | $0.3$         |
| Liver          | 81 (30%)             | 33 (29%) | 48 (30%) |                      |               |
| LN Only        | 51 (19%)             | 26 (23%) | 25 (16%) |                      |               |
| Visceral       | 139 (51%)            | 54 (48%) | 85 (54%) |                      |               |
| Unknown        | 27                   | 16       | 11        |                      |               |

$^1$n (%).
$^2$Pearson’s Chi-squared test; Fisher’s exact test.
HR, homologous recombination; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; TCGA, the cancer genome atlas; BCG: bacillus calmette guerin vaccine; IC, immune cells; TC, tumor cells.
higher in high grade bladder cancer and invasive bladder cancer ($p < 0.05$) than in low grade bladder cancer and superficial bladder cancer (Figures 9H, I). Kaplan-Meier survival analysis revealed that patients with high expression of $EME1$, $RAD51AP1$, and $RAD54L$ genes had a significantly shorter disease-specific survival time than patients with low expression of $EME1$, $RAD51AP1$, and $RAD54$ (Figures 9J–M).

Hub Gene Expression is Associated With Tumor Proliferation and Gene Mutation

The study discovered that the expression levels of hub genes such as $EME1$, $RAD51AP1$, and $RAD54L$ were highly positively correlated with Thorsson et al.’s proliferation characteristic data ($\text{cor} > 0.7$, $p < 0.001$), and moderately positively correlated with Th2 cells, Wound Healing, and DNA damage repair.
other characteristic data (cor > 0.4, \(p < 0.001\)) (Figures 10A–J). The study discovered that EME1, RAD51AP1, and RAD54L were substantially more prevalent in TP53 and RB1 mutant samples than in non-mutation samples (\(p < 0.05\)), as well as in high TMB and TNB samples than in low TMB and TNB samples (Figures 10K–N). The findings indicated that hub genes may enhance tumor growth and are associated with tumor mutation, which may affect immunotherapy.

**DISCUSSION**

Immunotherapy was discovered lately, and it now offers new therapeutic choices for individuals with advanced mUC, particularly those who are intolerant to platinum chemotherapy (Witjes et al., 2021). Based on the diversity in treatment among patients, the European Association of Urology recommends utilizing ICIs when the positive number of tumor-infiltrating immune cells evaluated by Ventana SP142 is greater than 5% (Cathomas et al., 2022). However, no attempt has been made to forecast mUC patients’ prognosis using tumor mutation-related characteristics.

The DDR signature genes were scored using ssGSEA, and the results revealed that HR and BER, NHEJ, TLS, and OTHER were all distinct. The effective group (CR/PR) had much higher HR scores than the ineffective group (SD/PD), whereas the effective group had significantly lower other features than the ineffective group. HR is a process for repairing double-strand DNA breaks that can be used exclusively during the S and G2 stages of the cell cycle due to its reliance on sister chromatids as repair templates (Talens et al., 2017). A recent study indicates that HR defects (HRD) in cancer might result in unrepaired double-strand DNA breaks, fork collapse, genotypically rearrangement, and increased tumor aggressiveness in breast and ovarian cancer (Bouwman et al., 2010; Piazza and Heyer, 2019; Vergote et al., 2021). On the other hand, increased HR repair protein production disrupts the HR repair process and promotes gene rearrangement, resulting in genomically instability (Richardson et al., 2004). Furthermore, HR-related genes have been found to be substantially expressed in cancer cells with low HR effectiveness, highlighting that this is a non-functional compensatory strategy in DNA damage repair-deficient malignancies (Pitroda et al., 2014). Patients with a HR deficiency in bladder cancer may benefit more from HRD-targeted platinum medications and PARP inhibitors, and no correlation between their functional activity and bladder cancer has been established (Börcsök et al., 2021). The HR
TABLE 3 | Univariate Cox regression analysis.

| Characteristic          | Beta   | Hazard ratio (95% CI for HR) | p Value |
|-------------------------|--------|-----------------------------|---------|
| Sex                     | −0.17  | 0.84 (0.6–1.2)              | 3.10E-01|
| IC level                | −0.34  | 0.71 (0.59–0.85)            | 2.10E-04|
| TC level                | −0.03  | 0.97 (0.95–0.99)            | 6.80E-01|
| TMB                     | −0.05  | 0.96 (0.93–0.98)            | 3.10E-04|
| TNB                     | −0.36  | 0.7 (0.59–0.83)             | 6.80E-05|
| Lund2                   | 0.19   | 1.2 (1.1–1.4)               | 1.80E-03|
| TCGA subtype            | 0.00   | 1 (0.88–1.1)                | 9.60E-01|
| HR score group          | −0.56  | 0.57 (0.42–0.77)            | 2.60E-04|
| Immune checkpoint       | −0.08  | 0.93 (0.87–0.99)            | 1.80E-02|
| 8 T effector            | −0.10  | 0.91 (0.86–0.95)            | 3.40E-04|
| DDR                     | −0.04  | 0.96 (0.94–0.99)            | 4.80E-03|
| APM                     | −0.07  | 0.93 (0.87–1)               | 4.50E-02|
| CC Reg                  | 0.10   | 1.1 (1–1.2)                 | 1.80E-02|
| Fanconi                 | −0.07  | 0.94 (0.9–0.97)             | 7.80E-04|
| Gene19                  | 0.03   | 1 (0.98–1.1)                | 2.40E-01|
| Toga                    | 0.01   | 1 (0.94–1.1)                | 8.30E-01|
| Histones                | −0.08  | 0.92 (0.85–1)               | 5.00E-02|
| EM1                     | 0.02   | 1 (0.95–1.1)                | 6.30E-01|
| EM2                     | 0.03   | 1 (0.96–1.1)                | 4.00E-01|
| EM3                     | 0.01   | 1 (0.94–1.1)                | 7.40E-01|
| WNT target              | 0.17   | 1.2 (1–1.4)                 | 8.30E-03|
| FGFR3 related           | 0.05   | 1.1 (0.96–1.2)              | 2.90E-01|
| Cell cycle              | −0.03  | 0.97 (0.95–0.99)            | 1.80E-02|
| Mismatch repair         | −0.06  | 0.95 (0.9–0.99)             | 2.70E-02|
| Homologous recombination| −0.08  | 0.93 (0.88–0.98)            | 3.40E-03|
| Nucleotide excision repair| −0.05  | 0.95 (0.91–1)               | 3.20E-02|
| DNA replication         | −0.04  | 0.96 (0.92–0.99)            | 1.50E-02|
| Base excision repair    | −0.05  | 0.95 (0.9–1)                | 4.20E-02|
| Risk score              | 0.82   | 2.3 (1.8–2.9)               | 5.70E-11|

**p < 0.001; ***p < 0.01; *p < 0.05.

TABLE 4 | Multivariate Cox regression analysis.

| Characteristic          | Beta   | Hazard ratio (95% CI for HR) | p Value |
|-------------------------|--------|-----------------------------|---------|
| Risk score              | 1.42   | 4.1 (2.4–7.1)               | 4.10E-07|
| TNB                     | −0.30  | 0.74 (0.61–0.91)            | 9.0039  |
| Mismatch Repair         | 0.13   | 1.1 (1–1.2)                 | 0.0033  |
| CC Reg                  | −0.16  | 0.86 (0.74–0.98)            | 0.03    |
| Immune Checkpoint       | 0.08   | 1.1 (0.97–1.2)              | 0.12    |

Global p-value (Log-Rank): 4.5977E-11; AIC: 1059.89; Concordance Index: 0.7.

**p < 0.001; ***p < 0.01; *p < 0.05.

TMB, tumor mutation burden; TNB, tumor neoantigen burden; IC, immune cells; TC, tumor cells; HR, homologous recombination; DDR, DNA, damage repair; APM: antigen processing and presentation machinery; CC, reg, cell cycle regulation.

The score of the genomically instability sample in the Lund2 subtype was significantly greater than that of the other subtypes, and the genomically instability sample composition in the effective group was significantly higher than that of the ineffective group in the immunotherapy response subgroup. This demonstrates that high HR scores are associated with immunotherapy responses and suggest genomically instability in bladder cancer. Additionally, a variety of other DDR function defects may result in genome and chromosome instability, which may result in DNA leakage from the nucleus to the cytoplasm, activation of cytoplasmic DNA sensors, activation of downstream pathways, including type I interferon response, and ultimately enhanced antitumor immunity, and may result in cancer cells being susceptible to ICIs (Chen et al., 2022). GO functional enrichment analysis showed that HR related modules were closely related to the cell cycle, cell cycle process, and mitotic cell cycle. Excessive cell division is connected with the management of the cell cycle in tumor cells, including cell cycle checkpoints, oncogene-induced replication needs, and mitotic checkpoints (Matthews et al., 2022). Additionally, the heat map demonstrated that samples with a high HR score expressed much more signature genes such as cell cycle, DNA replication, histone, DDR, immunological checkpoint, and CD8+ effector T cells than those with a low HR score. This shows that samples with a high HR score may be more genomically unstable and therefore more susceptible to immunotherapy.
Currently, most immunotherapy prediction models are based on immune cell infiltration. Chen et al. (2021), for example, developed a model based on the CD8+ effector T cell signature’s immune checkpoint signature. Based on the HR gene signature, the study created a 6-gene risk model. In both the training and internal validation groups, patients with a high risk score had a shorter overall survival time than patients with a low risk score, and the ROC curve verified this. This study found risk score and mismatch repair (MMR) to be independent risk factors for immunotherapy patients, proving the risk score’s predictive value. MMR defects result in base pair deletion or mutation at recurrent microsatellite loci, resulting in microsatellite instability (MSI), which is a type of genomic instability (Yoshioka et al., 2021). Defects in DNA double-strand repair have been demonstrated to cause MSI during replication stress in mouse embryonic fibroblasts (Matsumo et al., 2019). Considering HR repair is the primary form of DSB repair, defects in this way may cause MSI as well as MMR defects. Tumor patients with MSI have a substantial number of mutant neoantigens and showed susceptibility to ICIs in cancers of various tissue origins, according to Le et al. (2017), which was consistent with our findings. TNB and CC Reg both are protective factors in their own respect. TNB is more sensitive than TMB in predicting the success of ICIs since it measures the total quantity of neoantigens in tumor cells (Wang et al., 2021). Only a small percentage of mutations can be identified by positive T lymphocytes because not all tumor cell mutations yield neoantigens (Wang and Wang, 2017). The CC reg is also closely related to immunotherapy. By phosphorylating and stabilizing SPOP and boosting its binding to NFkB/P65, the cyclin D-CDK4/6 kinase can lower PDL1 expression, which is favorable to immunotherapy (Liu et al., 2022).

The study found RAD51AP1, RAD54L, and EME1 to be hub genes in HR patterns associated with immunotherapy response and tumor progression. RAD51AP1 stands for RAD51-associated protein 1. RAD51AP1 enhances RNA transcript entrance into donor DNA and increases HR by establishing a DR-loop when local transcription is active (Ouyang et al., 2021). Breast cancer,
colon cancer, and other cancers express it more. Its defects can slow tumor growth by impairing stem cell self-renewal and increase chemotherapy and radiation sensitivity (Bridges et al., 2020; Bridges et al., 2021). RAD54L is a Rad51 cofactor that participates in HR-related DNA damage repair via DNA-dependent double-stranded ATPase (Ceballos and Heyer, 2011). In bladder cancer, the transcription factor E2F1 directly activates RAD54L, regulating DDR, and is linked to poor prognosis (Mun et al., 2020). An endonuclease complex with methyl Methanesulfonate-sensitive UV-Sensitive 81 protein is encoded by EME1. In the absence of CHK1, this endonuclease complex divides poorly replicated chromosomes in mitosis, producing chromosomal instability and tumor development (Calzetta et al., 2020). The finding of these genes in various cancers is related to disease progression. Our study found a substantial correlation between RAD51AP1, RAD54L, and EME1 gene expression and bladder cancer proliferation, Th2, and wound healing scores. The expression levels of hub genes were also higher in the TP53 and RB1 mutant samples than in the non-mutant samples, and in the high TMB and TNB samples than in the low expression levels. This

**FIGURE 9 |** Analysis of relationship between HR related genes and clinical features in GSE133624 and GSE13507. (A–G). Differences in expression of HR-related genes between cancer and paired paracancer samples; (H,I). Expression differences of HR related genes in different tumor grades and invasive samples; (J–M), Kaplan-Meier survival analysis based on grouping of median expression values of HR related genes in GSE13507.
causes uncontrollable cell proliferation and genomically instability due to TP53 and RB1 mutations (McClintock, 1938; Frias et al., 2012). This may be the main mechanism acting on tumor mutations.

In a summary, the study discovered that a high HR score was associated with immune response and genomically instability. However, whether the process is driven by HR gene overexpression or by passive non-functional upregulation of HR-related genes caused by DNA damage repair errors remains uncertain, although this has no bearing on the subsequent prediction models’ construction. Additionally, the study identified hub genes related to immunotherapy and tumor growth in HR that will be exploited in future fundamental research.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

REFERENCES

Babjuk, M., Burger, M., Zigeuner, R., Shariat, S. F., van Rhijn, B. W. G., Compérat, E., et al. (2013). EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder: Update 2013. Eur. Urol. 64 (4), 639–653. doi:10.1016/j.eururo.2013.06.003

Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., et al. (2009). Systematic RNA Interference Reveals that Oncogenic KRAS-Driven Cancers Require TBK1. Nature 462 (7269), 108–112. doi:10.1038/nature08460

Berghlund, A. E., Welsh, E. A., and Eschrich, S. A. (2017). Characteristics and Validation Techniques for PCA-Based Gene-Expression Signatures. Int. J. Genomics 2017, 2354564. doi:10.1155/2017/2354564

AUTHOR CONTRIBUTIONS

The study conception and design were performed by PL and ZW. Material preparation, data collection, and analysis were performed by PL, CC, and JL. The first draft of the manuscript was written by PL. The manuscript was revised by JT and ZW. Other authors provided ideas for this study. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported by National Natural Science Foundation of China (Project number: 82060459, 82002678), Lanzhou Science and Technology Development Guiding Project (Project number: 2019-ZD-60), and the Fundamental Research Funds for the Central Universities (Project number: lzujbky-2021-kb29).
Li et al. Prognosis Prediction in Immunotherapy

Börtsch, J., Diesso, M., Sztpinszki, Z., Prosz, A., Tisza, V., Spišak, S., et al. (2021). Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer. *Cancer Res.* 71 (13), 3734–3743. doi:10.1158/0008-5472.CCR-20-5037

Bouman, P., Aly, A., Escandell, J. M., Pieterse, M., Bartkova, J., van der Gulden, H., et al. (2010). 33BP1 Loss Rescues BRCA1 Deficiency and Is Associated with Triple-Negative and BRCA-Mutated Breast Cancers. *Nat. Struct. Mol. Biol.* 17 (6), 688–695. doi:10.1038/nsmb.1831

Bridges, A. E., Ramachandran, S., Pathania, R., Parwal, U., Lester, A., Rajpurohit, P., et al. (2020). RAD51AP1 Deficiency Reduces Tumor Growth by Targeting Stem Cell Self-Renewal. *Cancer Res.* 80 (18), 3855–3866. doi:10.1158/0008-5472.CAN-19-3713

Bridges, A. E., Ramachandran, S., Tamizhmani, K., Parwal, U., Lester, A., Rajpurohit, P., et al. (2021). RAD51AP1 Loss Attenuates Colorectal Cancer Stem Cell Renewal and Sensitizes to Chemotherapy. *Cancer Res.* 80 (9), 1498–1497. doi:10.1158/1541-7786.mcr-20-0780

Calzetta, N. L., Besteiro, A. M. G., and Gottifredi, V. (2020). Mus81-Emel-Dependent Aberrant Processing of DNA Replication Intermediates in Mitosis Impairs Genome Integrity. *Sci. Adv.* 6 (50), eabc8257. doi:10.1126/sciadv.abc8257

Catamos, R., Lorch, A., Bruins, H. M., Comperat, E. M., Cowan, N. C., Efstratiou, J. A., et al. (2022). The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. *Eur. Urol.* 81 (1), 95–103. doi:10.1016/j.eururo.2021.09.026

Ceballos, S. J., and Heyer, W.-D. (2011). Functions of the Snf2/Swi2 Family Rpd5 Motor Protein in Homologous Recombination. *Biochim. Biophys. Acta (BBA) - Gene Regul. Mech.* 1809 (9), 509–523. doi:10.1016/j.bbagen.2011.06.006

Chan, T. A., Yarchoon, M., Jaffe, E., Swanton, C., Quezada, S. A., Stenzinger, A., et al. (2021). CD8+ T Effector Biomarker: Utility for the Oncology Clinic. *Br. J. Cancer.* 80 (18), 3855–3866. doi:10.1038/s41416-019-11760-2

Mathews, H. K., Bertoli, C., and De Bruin, R. A. M. (2022). Cell Cycle Control in Cancer. *Nat. Rev. Mol. Cell Biol.* 23 (1), 74–88. doi:10.1038/s41580-021-00403-4

Mccintock, B. (1938). The Production of Homologous Deficient Tissues with Mutant Characteristics by Means of the Aberrant Mitotic Behavior of Ring-Shaped Chromosomes. *Genetics* 23 (4), 315–376. doi:10.1093/genetics/23.4.315

Mun, J. Y., Baek, S. W., Park, W. Y., Kim, W. T., Kim, S. K., Roh, Y. G., et al. (2020). EZF1 Promotes Progression of Bladder Cancer by Modulating RAD51L Involved in Homologous Recombination Repair. *Int. J. Mol. Sci.* 21 (23), 9025. doi:10.3390/ijms21239025

Ouyang, J., Yadav, T., Zhang, J.-M., Yang, H., Rheinbay, E., Guo, H., et al. (2021). RNA Transcripts Stimulate Homologous Recombination by Forming DR-Loops. *Nature* 594 (7862), 283–288. doi:10.1038/d41586-021-03538-8

Park, B. R., Adamson, B. J. S., Khozin, S., Galsky, M. D., Baxi, S. S., Cohen, A., et al. (2019). Association between FDA Label Restriction and Immunotherapy and Chemotherapy Use in Bladder Cancer. *JAMA* 322 (12), 1209–1211. doi:10.1001/jama.2019.10650

Parks, S., Lee, H., Lee, S.-H., Sun, J.-M., Park, W.-Y., et al. (2019). DNA Damage Response and Repair Pathway Alteration and its Association with Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC. *J. Thorac. Oncol.* 14 (9), 1640–1650. doi:10.1016/j.jtho.2019.05.014

Patel, V. G., Oh, W. K., and Galsky, M. D. (2020). Treatment of Muscle-Invasive and Advanced Bladder Cancer in 2020. *CA A. Cancer J. Clin.* 70 (5), 404–423. doi:10.3322/caac.21631

Piazzo, A., and Heyer, W.-D. (2019). Homologous Recombination and the Formation of Complex Genomic Rearrangements. *Trends Cell Biol.* 29 (2), 135–149. doi:10.1016/j.tcb.2018.10.006

Pitroda, S. P., Pashtan, I. M., Logan, H. L., Budke, B., Darga, T. E., Weichselbaum, R. R., et al. (2014). DNA Repair Pathway Gene Expression Score Correlates with Repair Efficiency and Tumor Sensitivity to Chemotherapy. *Sci. Transl Med.* 6 (229), 229ra42. doi:10.1126/scitranslmed.3008291

Richardson, C., Stark, J. M., Ommundsen, M., and Jasim, M. (2004). Rad51 Overexpression Promotes Alternative Double-Strand Break Repair Pathways and Genome Instability. *Oncogene* 23 (2), 546–553. doi:10.1038/sj.onc.1207098

Saginala, K., Barsouk, A., Aluru, J. S., Rawla, P., Padala, S. A., and Barsouk, A. (2020). Epidemiology of Bladder Cancer. *Med. Sci. (Basel)* 8 (1), 15. doi:10.3390/medsci8010015

Shams, M. A., Shmooler Reis, R. J., Koley, H., Batchu, R. B., Li, C., and Munshi, N. C. (2009). Dysfunctional Homologous Recombination Mediates Genomic Instability and Progression in Myeloma. *Blood* 113 (10), 2290–2297. doi:10.1182/blood-2007-05-089193

Simon, N., Friedman, J., Hastie, T., and Tibshirani, R. (2011). Regularization Paths for Cox’s Proportional Hazards Model via Coordinate Descent. *J. Stat. Softw.* 39 (5), 1–13. doi:10.18637/jss.v039.i05

Song, D., Powles, T., Shi, L., Zhang, L., Ingersoll, M. A., and Lu, Y. J. (2019). Bladder Cancer, a Unique Model to Understand Cancer Immunity and Develop Immunotherapy Approaches. *J. Pathol.* 249 (2), 151–165. doi:10.1002/path.5306

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and
Mortality Worldwide for 36 Cancers in 185 Countries. *CA A. Cancer J. Clin.* 71 (3), 209–249. doi:10.3322/caac.21660
Talens, F., Jalving, M., Gietema, J. A., and Van Vugt, M. A. (2017). Therapeutic Targeting and Patient Selection for Cancers with Homologous Recombination Defects. *Expert Opin. Drug Discov.* 12 (6), 565–581. doi:10.1080/17460441.2017.1322061
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T. H., et al. (2018). The Immune Landscape of Cancer. *Immunity* 48 (4), 812–e14. doi:10.1016/j.immuni.2018.03.023
Topalian, S. L., Taube, J. M., Anders, R. A., and Pardoll, D. M. (2016). Mechanism-Driven Biomarkers to Guide Immune Checkpoint Blockade in Cancer Therapy. *Nat. Rev. Cancer* 16 (5), 275–287. doi:10.1038/nrc2016.36
Vergote, I., González-Martín, A., Ray-Coquard, I., Harter, P., Colombo, N., Pujol, P., et al. (2021). European Experts Consensus: BRCA/Homologous Recombination Deficiency Testing in First-Line Ovarian Cancer. *Ann. Oncol.* 33 (3), 276–287. doi:10.1016/j.annonc.2021.11.013
Zeng, D., Ye, Z., Shen, R., Yu, G., Wu, J., Xiong, Y., et al. (2021). IOBR: Multi-Omics Immuno-Oncology Biological Research to Decode Tumor Microenvironment and Signatures. *Front. Immunol.* 12, 687975. doi:10.3389/fimmu.2021.687975
Zhang, B., and Horvath, S. (2005). A General Framework for Weighted Gene Co-Expression Network Analysis. *Stat. Appl. Genet. Mol. Biol.* 4, 17. doi:10.2202/1544-6115.1128

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Li, Chen, Li, Yang, Wang, Dong, Mi, Zhang, Wang, Rodriguez, Tian and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.